Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
Discover
Related topics
Recent publication of in-vivo two-photon intravital imaging study targeting mouse kidney
May 22, 2023
In vivo longitudinal 920 nm two-photon intravital kidney imaging of a dynamic 2,8-DHA crystal
formation and...
Webinar: Multimodal tissue imaging and machine learning to advance precision medicine
May 17, 2023
Join us for this webinar to learn how the Orion spatial biology imaging platform was used to identify prognostic...
May 5, 2023
Decision to improve the output in a lab is always taken based on knowledge and workflow needs. But final decision to...
Real-Time and Quantitative Analysis of Macrophage Phagocytosis with RTCA eSight
May 4, 2023
The eSight is currently the only instrument that interrogates cell health and behavior using cellular
impedance...
Revolutionize your Flow Cytometry and Sorting workflow with Cytek Biosciences
May 3, 2023
Using full spectrum flow cytometry, Cytek systems ( RUO and CE-IVD) detect the entire fluorochrome emission, allowing...
Thermal Shift Assay using SYPRO Orange to Detect Protein Melting Temperatures
May 2, 2023
The thermal shift assay is based on temperature-induced denaturation and can be monitored using SYPRO Orange. This...
A deep learning and Monte Carlo based framework for bioluminescence imaging center Maastro
Apr 20, 2023
"In this paper,we developed a framework using deep learning for bioluminescence-based targeting for GBM animal...
Gentle sorting of microbial cells and sub-micron particles using WOLF sorter
Apr 18, 2023
While most modern applications of flow cytometry may focus on cells of eukaryotic origin, the first flow analyzers were...
InAlyzer to evaluate G6PD activity in relation with frailty
Mar 28, 2023
InAlyzer is body densitometry instrument for lab animals, equipped with 2 X-Ray sources and able to provide valuable...
Cardiomyocyte isolation using Cellenion’s cellenONE instrument
Mar 24, 2023
The cellenONE platform is ideal for the isolation of fragile and heterogeneous cell size populations, such as...
Jun 4, 2018
Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.
The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.
Related technologies: Conventional flow cytometry
Brand profile
Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
More info at:
www.aceabio.com